Core Insights - The company achieved a total operating revenue of 653 million yuan in H1 2025, representing a year-on-year growth of 1.72%, and a net profit attributable to shareholders of 38 million yuan, with a year-on-year increase of 33.37% [1] - The gross profit margin increased by 1.86 percentage points, indicating improved profitability [1] Revenue Breakdown - Revenue from proprietary products reached 203 million yuan, up 14.04% year-on-year, accounting for 31.09% of total revenue, an increase of 3.36 percentage points [1] - Revenue from self-produced artificial crystals contributed 171 million yuan, growing by 11.4% year-on-year, driven by national procurement policies and stable growth in overseas markets [1] - Revenue from distribution products was 327 million yuan, down 6.81% year-on-year, making up 50.09% of total revenue [1] Technical Services Performance - The technical services business showed steady growth, with revenue of 119 million yuan in H1 2025, an increase of 8.26% year-on-year, and accounting for 18.24% of total revenue, up 1.10 percentage points [1] - The company has a technical service team of 135 engineers in the Greater China region, serving nearly 14,000 clients across 13 service centers [1] R&D Investment - The company has 252 R&D personnel, representing approximately 28.0% of total employees, with R&D bases in Shenzhen, Suzhou, Wuxi, and Wenzhou domestically, and in the Netherlands and Germany internationally [2] - R&D expenditure for H1 2025 was 43.4 million yuan, a year-on-year increase of 23.6%, accounting for 21.4% of proprietary product revenue [2] Future Projections - Revenue projections for 2025-2027 are 1.564 billion, 1.715 billion, and 1.875 billion yuan, with year-on-year growth rates of 9.48%, 9.67%, and 9.33% respectively [2] - Net profit projections for the same period are 135 million, 180 million, and 214 million yuan, with year-on-year growth rates of 45.85%, 33.71%, and 18.99% respectively [2]

Gaush Meditech Ltd 高視醫療科技有限公司 (Incorporated in the Cayman Islands with limited liability) （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） (Stock Code: 2407) （股 份 代 號：2407） NOTIFICATION LETTER 通知信函 Dear Registered Shareholders: 25 September 2025 Gaush Meditech Ltd (the "Company") – Notice of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at www.gaush.com and the websit ...

Gaush Meditech Ltd 高視醫療科技有限公司 (Incorporated in the Cayman Islands with limited liability) （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） Gaush Meditech Ltd (the "Company") — Notification of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.gaush.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the ...

Financial Performance - The company's revenue for the six months ended June 30, 2025, was RMB 653.1 million, an increase of 1.7% compared to RMB 642.0 million for the same period in 2024[11]. - The net profit for the same period was RMB 35.9 million, representing a 33.5% increase from RMB 26.9 million in 2024[11]. - Basic earnings per share for the six months ended June 30, 2025, were RMB 0.26, up from RMB 0.19 in 2024[11]. - The group's total revenue increased by 1.7% from RMB 642.0 million for the six months ended June 30, 2024, to RMB 653.1 million for the six months ended June 30, 2025[28]. - Gross profit for the same period was RMB 315,664,000, compared to RMB 298,353,000 in 2024, reflecting a growth of about 5.79%[93]. - The total comprehensive income for the period was RMB 135,868,000, significantly higher than RMB 7,110,000 in 2024, showing a substantial increase[94]. - The company achieved a net profit of RMB 35,894,000 for the six months ended June 30, 2025, up from RMB 26,928,000 in 2024, indicating an increase of approximately 33.1%[93]. Research and Development - Research and development expenses for the six months ended June 30, 2025, were RMB 43.4 million, a 23.6% increase from RMB 35.1 million in 2024, accounting for 6.6% of total revenue[11]. - Significant advancements in R&D include the registration of the T3-600 and T3-400 corneal confocal microscopes and the launch approval of a fundus camera in 2025[13]. - The group has a total of 252 R&D personnel, accounting for approximately 28.0% of total employees, with R&D expenses amounting to RMB 43.4 million, a year-on-year increase of 23.6%[19]. - The group aims to enhance its product revenue structure by increasing R&D investment, particularly in high-end ophthalmic medical devices[26]. - The group has established a "4+2" global R&D layout, with domestic bases located in Shenzhen, Suzhou, Wuxi, and Wenzhou, and overseas bases in the Netherlands and Germany[19]. Product and Market Development - The company has a product portfolio of 165 items, including 72 proprietary products, with a focus on expanding its proprietary product offerings[13]. - Revenue contribution from proprietary products was RMB 203.0 million, accounting for 38.3% of total sales, up from 33.6% in the same period of 2024[15]. - Revenue from distribution products was RMB 327.1 million, a decrease of 6.8% year-on-year[17]. - The company has established exclusive distribution agreements with 15 overseas brand partners, including Heidelberg and Quantel Medical[13]. - The group’s products have been sold in 51 countries and regions, with a focus on expanding its international market presence[24]. Financial Management - Financing costs decreased significantly by 49.0% from RMB 20.6 million to RMB 10.5 million, attributed to the repayment of bank loans and a decrease in interest rates[35]. - The debt-to-asset ratio decreased from 34.8% as of December 31, 2024, to 28.0% as of June 30, 2025, indicating improved financial stability[53]. - The company reported a foreign exchange gain of RMB 100.0 million for the six months ended June 30, 2025, primarily due to fluctuations in the euro exchange rate during the reporting period[56]. - The company has maintained a leverage ratio not exceeding 3.50:1, with an interest coverage ratio of no less than 4.00:1 as of June 30, 2025[136]. Operational Efficiency - Selling and distribution expenses remained relatively stable, increasing by 0.1% from RMB 115.5 million to RMB 115.6 million, with the percentage of these expenses to revenue decreasing from 18.0% to 17.7%[33]. - Administrative expenses rose by 15.9% from RMB 73.6 million to RMB 85.3 million, mainly due to the expansion of the management team in the R&D sector[34]. - The total employee cost for the reporting period was RMB 192.1 million, an increase from RMB 184.0 million for the same period in 2024, with a total of 819 employees as of June 30, 2025, down from 884 employees at the end of 2024[62]. Corporate Governance - The audit committee consists of two independent non-executive directors and one non-executive director, overseeing financial reporting and risk management[70]. - Major shareholders include GT HoldCo with 63,263,528 shares, representing 42.78% of the issued share capital[76]. - The company has complied with all applicable corporate governance codes during the reporting period[66]. - The company continues to review and monitor its corporate governance practices to ensure compliance[67]. Cash Flow and Assets - As of June 30, 2025, the company maintained a cash and cash equivalents balance of RMB 323.2 million, a decrease of 23.3% from RMB 421.4 million as of December 31, 2024, mainly due to loan repayments totaling approximately RMB 149.7 million during the reporting period[50]. - The company's capital expenditure for the six months ended June 30, 2025, was RMB 12.7 million, compared to RMB 10.2 million for the same period in 2024, primarily for purchasing production equipment for self-developed products[52]. - Total liabilities decreased to RMB 462,434,000 as of June 30, 2025, from RMB 466,310,000 at the end of 2024, a reduction of 0.62%[97]. - The company reported a decrease in cash and cash equivalents to RMB 323,187,000 as of June 30, 2025, down from RMB 421,438,000 at the end of 2024, a decline of 23.36%[96]. Acquisitions and Investments - The company acquired 100% of the Korean artificial crystal business for a total consideration of RMB 1,852,000, with an initial payment of RMB 1,852,000 made at the acquisition date[139][141]. - Revenue from the Korean artificial crystal business from the acquisition date to June 30, 2025, was RMB 1,825,000, with a profit of RMB 1,232,000 during the same period[145]. - The identifiable net assets of the acquired Korean artificial crystal business amounted to RMB 1,004,000, with goodwill generated from the acquisition totaling RMB 848,000[142]. Shareholder Information - The total issued shares remained at 147,887,869 as of June 30, 2025, unchanged from the previous reporting period[138]. - The proposed final dividend for the year ended December 31, 2024, is HKD 0.30 per ordinary share, as announced at the annual general meeting on May 29, 2025[121]. - No interim dividend is recommended for the six months ending June 30, 2025, consistent with the previous period[69].

Group 1 - The core viewpoint of the report is that Gaoshi Medical (02407) is expected to see revenue growth from 2025 to 2027, with projected revenues of 1.564 billion, 1.715 billion, and 1.875 billion yuan, representing year-on-year growth rates of 9.48%, 9.67%, and 9.33% respectively [1] - The net profit attributable to the parent company is forecasted to be 135 million, 180 million, and 214 million yuan for the same period, with year-on-year growth rates of 45.85%, 33.71%, and 18.99% [1] - The report maintains a "buy" rating for the company, highlighting its global "4+2" research and development layout and continuous investment in R&D [1] Group 2 - In the first half of 2025, the company achieved total operating revenue of 653 million yuan, a year-on-year increase of 1.72%, and a net profit attributable to the parent company of 38 million yuan, reflecting a year-on-year growth of 33.37% [1] - The gross profit margin increased by 1.86 percentage points [1] - Revenue from self-owned products reached 203 million yuan in the first half of 2025, a year-on-year increase of 14.04%, accounting for 31.09% of total revenue, an increase of 3.36 percentage points [1] Group 3 - The revenue from self-produced artificial crystals was 171 million yuan, with a year-on-year growth of 11.4%, driven by improved customer coverage and usage due to national procurement policies [1] - Revenue from distributed products was 327 million yuan, a year-on-year decrease of 6.81%, accounting for 50.09% of total revenue [1] - The company's technical service business also showed steady growth, with revenue of 119 million yuan in the first half of 2025, an increase of 8.26%, and accounting for 18.24% of total revenue [2] Group 4 - As of the first half of 2025, the company had a technical service team of 135 engineers, serving nearly 14,000 clients across 13 service centers in Greater China [2] - The company has a total of 252 R&D and production personnel, making up approximately 28.0% of the total workforce [2] - R&D expenditures in the first half of 2025 amounted to 43.4 million yuan, a year-on-year increase of 23.6%, representing 21.4% of self-owned product revenue [2]

Group 1 - The core viewpoint of the report is that Gaoshi Medical is expected to see steady revenue growth from 2025 to 2027, with projected revenues of 1.564 billion, 1.715 billion, and 1.875 billion yuan, representing year-on-year growth rates of 9.48%, 9.67%, and 9.33% respectively [1] - The net profit attributable to the parent company is forecasted to be 135 million, 180 million, and 214 million yuan for the same period, with year-on-year growth rates of 45.85%, 33.71%, and 18.99% respectively [1] - The company maintains an "overweight" rating based on its global "4+2" R&D layout and continuous investment in research and development, which has led to an expanding portfolio of proprietary products [1] Group 2 - In the first half of 2025, the company achieved total operating revenue of 653 million yuan, a year-on-year increase of 1.72%, and a net profit of 38 million yuan, up 33.37% year-on-year [1] - The gross margin increased by 1.86 percentage points, indicating improved profitability [1] - Revenue from proprietary products reached 203 million yuan, a year-on-year increase of 14.04%, accounting for 31.09% of total revenue, an increase of 3.36 percentage points [1] Group 3 - The revenue from self-produced artificial crystals contributed 171 million yuan, with a year-on-year growth of 11.4%, driven by national procurement policies enhancing customer coverage and usage, along with stable growth in overseas artificial crystal business [1] - Revenue from distributed products was 327 million yuan, a year-on-year decline of 6.81%, accounting for 50.09% of total revenue [1] Group 4 - The company's technical service business also showed steady growth, with revenue of 119 million yuan in the first half of 2025, an increase of 8.26% year-on-year, and accounting for 18.24% of total revenue, an increase of 1.10 percentage points [2] - As of the first half of 2025, the company had a technical service team of 135 engineers, serving nearly 14,000 clients across 13 service centers in Greater China [2] - The company invested significantly in R&D across various product lines, with R&D expenses of 434 million yuan in the first half of 2025, a year-on-year increase of 23.6%, representing 21.4% of proprietary product revenue [2]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected investment return that exceeds the market benchmark by more than 5% to 20% over the next 6-12 months [4][9]. Core Insights - The company achieved a total revenue of 653 million yuan in the first half of 2025, representing a year-on-year growth of 1.72%, while the net profit attributable to shareholders reached 38 million yuan, up 33.37% year-on-year [1][4]. - The company's self-owned product revenue increased to 203 million yuan, a growth of 14.04% year-on-year, accounting for 31.09% of total revenue, with significant contributions from self-produced artificial crystals [1][2]. - The company has a robust R&D investment strategy, with R&D expenses amounting to 434 million yuan in the first half of 2025, a 23.6% increase year-on-year, representing 21.4% of self-owned product revenue [2][4]. Financial Performance Summary - For the fiscal years 2025 to 2027, the company is projected to achieve revenues of 1.564 billion, 1.715 billion, and 1.875 billion yuan, with respective growth rates of 9.48%, 9.67%, and 9.33% [2][8]. - The net profit attributable to shareholders is expected to grow to 135 million, 180 million, and 214 million yuan over the same period, with growth rates of 45.85%, 33.71%, and 18.99% respectively [2][8]. - The earnings per share (EPS) are projected to be 0.91, 1.22, and 1.45 yuan for 2025, 2026, and 2027, respectively [2][8].

Group 1 - The executive director Zhao Xinli increased his stake in Gaoshi Medical (02407) by purchasing 5,900 shares at a price of 7.37 HKD per share, totaling approximately 43,500 HKD [1] - After the purchase, Zhao's total shareholding in Gaoshi Medical is approximately 3.6449 million shares, representing a holding percentage of 2.46% [1]

智通财经APP获悉，香港联交所最新资料显示，8月29日，执行董事赵新礼增持高视医疗(02407)5900 股，每股作价7.37港元，总金额约为4.35万港元。增持后最新持股数目约为364.49万股，最新持股比例 为2.46%。 ...

Summary of the Conference Call for Gaoshi Medical Company Overview - **Company**: Gaoshi Medical - **Industry**: Medical Devices, specifically Ophthalmology Key Financial Performance - Total revenue for H1 2025 reached **653 million RMB**, a **1.7%** increase year-on-year from **642 million RMB** in the same period last year [2][3] - Gross profit was **316 million RMB**, with a gross margin of **48.4%**, up **1.8 percentage points** year-on-year [3] - Net profit amounted to **35.9 million RMB**, reflecting a **33.5%** increase year-on-year [2][3] Revenue Breakdown - **Self-owned business revenue**: **322 million RMB**, accounting for **49%** of total revenue, with a significant contribution from artificial lenses [2][4] - Artificial lens revenue: **170 million RMB**, up **11.4%** year-on-year [4] - Mid-to-high-end lens growth: **25.1%** [4] - **Distribution business revenue**: **327 million RMB**, down **6.8%** year-on-year, representing **51%** of total revenue [2][7] - **Overseas market revenue**: **171 million RMB**, a **17.6%** increase year-on-year, accounting for **26.2%** of total revenue [2][9] Product and Service Developments - **Technical services revenue**: **119 million RMB**, up **8.3%** year-on-year, with an engineering team of **135 members** and **14,000 service instances** [2][6] - New partnerships and products introduced, including the Heidelberg three-in-one ophthalmic diagnostic platform and Sirin's all-laser surgical system [7] - R&D investment reached **43.4 million RMB**, a **23.6%** increase year-on-year, representing **6.6%** of total revenue [2][10] Market Strategy and Future Plans - Focus on **13 global mid-to-high-end lens markets**, transitioning to a direct sales model, with Brazil expected to launch three series by year-end [2][9][12] - Plans to enhance product lines with new registrations for various self-owned products, including **ultrasonic phacoemulsification devices** and **OK lenses** [12][24] - Emphasis on increasing the coverage of high-end lenses in the Chinese market while expanding internationally [17][18] Competitive Advantages - Strong performance in the domestic artificial lens market, with a **80%** increase in multi-focal and toric lens implantations [15][16] - Strategic positioning to leverage the national procurement policy to enhance product penetration and market share [18][19] Cash Flow and Debt Management - Significant improvement in operating cash flow due to increased cash receipts from sales and reduced procurement costs [13] - Debt structure improved following the repayment of a merger loan [13] Investor Relations and Communication - Plans for investor engagement through open days in Wuxi or Shenzhen to discuss corporate culture, core products, and market strategies [34][35] Industry Trends - The ophthalmology industry has seen rapid growth post-pandemic, with increasing domestic replacements and new entrants in the medical device sector [32] - Gaoshi Medical is positioned to benefit from advancements in supply chains and talent systems within the industry [32][33] Conclusion Gaoshi Medical demonstrates robust financial growth, strategic market positioning, and a commitment to innovation in the ophthalmology sector, with plans for continued expansion and investor engagement in the coming years.